Business
Mydecine (OTC: MYCOF, NEO: MYCO) is an aspiring psychedelics medicine company that aims to use psilocybin, the active ingredient in...
Nova Mentis says that psilocybin could be a novel, first-in-class treatment for a brain disorder that leads to learning disabilities...
According to the CDC, about 166 Americans die from TBI-related conditions each day....
As technological change revolutionizes medicine and healthcare, how do we ensure that no-one, particularly members of vulnerable groups, get left...
The Vancouver-based company says it has overcome the challenges of natural extraction with its new technology, which can produce superior...
Another clinic gets approval to conduct MDMA research, and new psychedelic research facilities open in Australia and the U.S., plus...
CEO Christopher Dawson and COO Andrew Galloway spent years working in clinical mental health treatment centers before betting big on...
MindMed's Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED's previous CEO, Jr Rahn....
"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential...
"Based on our research, we think we're able to get to psilocybin in fewer steps than any of the other...